GSK’s oncology and HIV drugs drive 7% sales rise in 2025
The company is hoping that its accelerated R&D strategy and new launches will help offset the impact of upcoming patent expiries within its portfolio.
Therapy Area
Corxel raises $287m as obesity continues to spark investor interest
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
J&J’s Caplyta doubles remission rate in MDD patients
JPM26: Enanta outlines strategy to lead in RSV therapeutics
JPM26: AstraZeneca bids to accelerate oncology R&D with Modella AI acquisition
Drugmakers welcome FDA’s GLP-1RA suicide warning removal request
JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions
